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Introduction {#jdi12172-sec-0005}
============

Chronic kidney disease (CKD) is highly prevalent worldwide, and is now recognized as a global public health problem with adverse outcomes of kidney failure, cardiovascular diseases and premature death[1](#jdi12172-bib-0001 jdi12172-bib-0002){ref-type="ref"}. In the USA and Australia, 11 --16% of the general population has CKD[3](#jdi12172-bib-0003 jdi12172-bib-0004){ref-type="ref"}. Studies from Europe have shown a similar high prevalence of CKD in the general population[5](#jdi12172-bib-0005){ref-type="ref"}. CKD is also highly prevalent in developing countries[6](#jdi12172-bib-0006 jdi12172-bib-0007){ref-type="ref"}. Based on a nationwide survey in China[8](#jdi12172-bib-0008){ref-type="ref"}, the prevalence of CKD was 10.8%, but awareness of CKD among the survey participants was just 12.5%. Given the high prevalence and the low awareness of CKD, identifying and treating the risk factors for early CKD might be the best approach to prevent or delay adverse outcomes.

Microalbuminuria is an early marker of CKD and vascular dysfunction, and is associated with end‐stage renal disease, and cardiovascular mortality and morbidity in both the high‐risk and general population[9](#jdi12172-bib-0009 jdi12172-bib-0010 jdi12172-bib-0011){ref-type="ref"}. The reference method to measure urinary albumin excretion is 24‐h urine collection. This is impractical for a large‐scale population‐based survey. A commonly used substitute is the urinary albumin‐to‐creatinine ratio (ACR; ACR ≥30 mg/g indicating microalbuminuria; first morning specimen preferred), which is recommended by the National Kidney Foundation[12](#jdi12172-bib-0012){ref-type="ref"}. However, this definition of microalbuminuria does not take into account sex differences in creatinine excretion, which have been advocated by Warram *et al*.[13](#jdi12172-bib-0013){ref-type="ref"} Furthermore, several studies have shown the continuous relationship between ACR values and increased cardiovascular risk[14](#jdi12172-bib-0014 jdi12172-bib-0015 jdi12172-bib-0016 jdi12172-bib-0017){ref-type="ref"}. Thus, the definition of ACR above 30 mg/g as albuminuria might be arbitrary.

The present study, based on a nationally representative sample of Chinese participants, first compared the differences in metabolic disorders within the microalbuminuria (ACR 30 --300 mg/g) group and the further subdivided normalbuminuria group. Then we examined the risk factors related to the presence of albuminuria, and the relationship between albuminuria levels and cardiovascular disease (CVD). We also analyzed how the use of a single ACR cut‐point vs sex‐specific ACR cut‐points, measured in a first‐morning urine sample, affects the estimated prevalence of microalbuminuria.

Materials and Methods {#jdi12172-sec-0006}
=====================

The data we used in the current study were from the China National Diabetes and Metabolic Disorders Study, which was a cross‐sectional survey of Chinese adults from June 2007 to May 2008. The study population and design have been described in detail previously[18](#jdi12172-bib-0018){ref-type="ref"}. We used a multistage sampling design in this survey. First, a total of 152 cities and 112 counties were selected from around the country based on geographical distribution, economic development, and urbanization. Then individuals who had been residents for more than 5 years were randomly chosen from each region. Exclusion criteria in the present study were as follows: (i) subjects with incomplete demographic information and missing data (mainly regarding fasting/2‐h glucose and urinary ACR); (ii) subjects with a previous diagnosis of diabetes or CKD; (iii) subjects with clinical evidence of urinary tract infection; and (iv) subjects with albuminuria above 300 mg/g. The total number of participants selected in the survey was 38,203.

The study protocol was approved by an institutional review board or an independent ethics committee at each participating institution. Informed written consent was requested from each subject before data collection.

Data Collection {#jdi12172-sec-0007}
---------------

Study participants were interviewed privately, face‐to‐face by trained interviewers using standard questionnaires. Information on demographics, education, lifestyle risk factors, and medical and drug history was collected. Questions related to the diagnosis and treatment of diabetes, hypertension, dyslipidemia and cardiovascular events were included. Anthropometric measures including weight, height, waist circumference (WC) and blood pressure were obtained according to a standard protocol.

After a minimum 10 h of fasting overnight, all participants without known diabetes underwent a standard oral glucose tolerance test (75 g anhydrous glucose in 250 mL water) at each examination. Fasting plasma glucose (FPG), fasting insulin, 2‐h plasma glucose (2hPG) and insulin were measured. Blood samples for glucose measurements were taken in sodium fluoride tubes. Plasma glucose was analyzed using the hexokinase enzymatic method. Insulin was measured by radioimmunoassay using a specific antibody. Homeostasis model assessment (HOMA) was used to evaluate the islet β‐cell function. Urinary albumin and creatinine were measured from a fresh morning spot urine sample stored at 4°C for \<1 week. Urinary albumin was measured with immunoturbidimetric tests. Urinary creatinine was measured with Jaffe\'s kinetic method. The urinary ACR was calculated to determine the categories for different levels of albuminuria. Serum total cholesterol (TC), triglycerides (TG), and low‐ and high‐density lipoprotein cholesterol (LDL‐C, HDL‐C) were determined with enzymatic methods.

All of the laboratory data were measured at the clinical biochemical laboratories in each province. Each study laboratory successfully completed a standardization and certification program.

Diabetes Assessment {#jdi12172-sec-0008}
-------------------

The World Health Organization (1999) diagnostic criteria were used to classify participants into different categories of glucose intolerance as follows: normal glucose tolerance (NGT; FPG \<6.1 mmol/L, 2hPG \<7.8 mmol/L); isolated impaired fasting glucose (I‐IFG; FPG ≥6.1 mmol/L, but \<7.0 mmol/L, 2hPG \<7.8 mmol/L); isolated impaired glucose tolerance (I‐IGT; FPG \<6.1 mmol/L, 2hPG ≥7.8 mmol/L, but \<11.1 mmol/L); IFG/IGT (FPG ≥6.1 mmol/L, but \<7.0 mmol/L, 2hPG ≥7.8 mmol/L, but \<11.1 mmol/L); and newly diagnosed type 2 diabetes mellitus (FPG ≥7.0 mmol/L, 2hPG ≥11.1 mmol/L, and no history of diabetes). Impaired glucose regulation (IGR) was defined as either IFG or IGT.

Definition of Other Variables {#jdi12172-sec-0009}
-----------------------------

We defined microalbuminuria[12](#jdi12172-bib-0012){ref-type="ref"} as a urinary ACR of 30 --300 mg/g. We also used sex‐specific ACR cut‐points, proposed by Rong Xu *et al*.[13](#jdi12172-bib-0013 jdi12172-bib-0019){ref-type="ref"}, 14 mg/g and 20 mg/g for men and women as the normal upper limit of ACR.

The prevalence of albuminuria was compared by using different diagnosis criteria of metabolic syndrome (MS) in the present study. According to the criteria of the Chinese Diabetes Society (CDS) in 2007[20](#jdi12172-bib-0020){ref-type="ref"}, MS could be diagnosed if three or more of the following abnormalities were present: (i) central obesity (WC ≥90 cm for men or ≥85 cm for women); (ii) elevated plasma glucose (FPG ≥6.1 mmol/L or 2hPG ≥7.8 mmol/L) or previously diagnosed diabetes mellitus; (iii) elevated blood pressure (≥130/85 mmHg or current treatment for hypertension) or previously diagnosed hypertension; (iv) elevated TG (TG ≥1.7 mmol/L); and (v) reduced HDL‐C (\<1.04 mmol/L). The International Diabetes Federation (IDF) criteria of MS[21](#jdi12172-bib-0021){ref-type="ref"} used central obesity (WC ≥90 cm for South Asian men or ≥80 cm for South Asian women) as a mandatory criterion, and the presence of at least two of the following four criteria: (i) TG ≥1.7 mmol/L; (ii) HDL‐C \< 1.0 mmol/L (40 mg/dL) for men or \<1.29 mmol/L (50 mg/dL) for women; (iii) blood pressure ≥130/85 mmHg or receiving drug treatment; and (iv) FPG ≥5.6 mmol/L (100 mg/dL).

Hypertension was diagnosed as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg, or receiving antihypertensive therapy for diagnosed hypertension[22](#jdi12172-bib-0022){ref-type="ref"}.

Dyslipidemia was defined as: (i) elevated TC ≥5.18 mmol/L; (i) elevated TG ≥1.70 mmol/L; (iii) reduced HDL‐C \< 1.04 mmol/L; (iv) elevated LDL‐C ≥ 3.37 mmol/L; or (v) drug treatment for lipid abnormality[20](#jdi12172-bib-0020){ref-type="ref"}.

Although the homeostasis model assessment of insulin resistance (HOMA‐IR) has been widely used, its cut‐off for insulin resistance (IR) has not been conclusive[23](#jdi12172-bib-0023 jdi12172-bib-0024){ref-type="ref"}. In the present study, from a group of NGT participants without obesity or hypertension or dyslipidemia, we selected the 75th percentile value 1.79 as the cut‐off point to define IR. This point is consistent with the that reported by Esteghamati *et al*.[24](#jdi12172-bib-0024){ref-type="ref"}

Statistical Analysis {#jdi12172-sec-0010}
--------------------

All participants were categorized by different levels of ACR (0 --10 mg/g, 10 --20 mg/g, 20 --30 mg/g, 30 --300 mg/g). Multivariate analyses of variance and χ^2^‐tests were used to examine differences in means and proportions, respectively. For continuous variables that do not follow normal distribution, natural logarithmic transformation was applied before analyzing. Data re presented as mean ± standard error for continuous variables with normal distribution, interquartile range for continuous variables with highly skewed distribution, and as percentages for categorical variables. The variables age, sex, glucose tolerance status, hypertension, dyslipidemia, body mass index (BMI; or abdominal obesity), insulin resistance, cardiovascular or cerebrovascular disease (CVD) history, diabetes mellitus family history (DMFH) and MS, explored as categorical variables, were included as potential variables in the backwards stepwise logistic regression model to determine associations with albuminuria. The adjusted odds ratio (OR) of CVD was also calculated for the different groups based on ACR levels. A two‐sided *P*‐value \< 0.05 was considered as statistically significant. Statistical analyses were carried out using [spss]{.smallcaps} 13.0 (SPSS Inc., Chicago, IL, USA).

Results {#jdi12172-sec-0011}
=======

The present study analyzed 38,203 participants, including 15,003 men and 23,200 women, with an average age of 44.5 ± 13.5 years. The total prevalence of albuminuria was 19.5% (16.4% in men, 21.7% in women) according to a single ACR cut‐point, and 33.3% (34.8% in men, 32.3% in women) according to sex‐specific cut‐points. Table [1](#jdi12172-tbl-0001){ref-type="table-wrap"} shows the clinical characteristics of study participants divided according to the ACR levels (0 --10 mg/g; 10 --20 mg/g; 20 --30 mg/g; 30 --300 mg/g). Participants with higher ACR levels tended to be older, women, and with increased blood glucose, BMI, WC, SBP, DBP, TC, TG, LDL‐C, HOMA‐IR, and uric acid. Participants in the higher‐ACR level group were also more likely to have abnormal glucose metabolism or diabetes, hypertension, dyslipidemia, obesity, insulin resistance and CVD history.

###### Characteristics of the total study group

                                                         ACR (mg/g)                                                                                                                                                                      
  ------------------------------------------------------ -------------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  *n*                                                    17,564               9,423                                                  3,765                                                                                               7,451
  Men (%)                                                45.49                35.02[\*](#jdi12172-note-0001){ref-type="fn"}          33.60[\*](#jdi12172-note-0001){ref-type="fn"}                                                       32.86[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}
  Age (years)                                            43.3 (0.10)          44.6 (0.14)[\*](#jdi12172-note-0001){ref-type="fn"}    45.5 (0.22)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}          47.2 (0.16)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  FPG (mmol/L)                                           5.17 (0.01)          5.22 (0.01)[\*](#jdi12172-note-0001){ref-type="fn"}    5.36 (0.02)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}          5.49 (0.01)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  2hPG (mmol/L)                                          6.36 (0.03)          6.56 (0.03)[\*](#jdi12172-note-0001){ref-type="fn"}    6.95 (0.05)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}          7.21 (0.03)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  FINS (mU/L)[§](#jdi12172-note-0001){ref-type="fn"}     7.0 (5.0--9.6)       7.0 (5.0--9.7)                                         7.4 (5.3--10.2)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}      7.8 (5.5--10.7)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}
  2hPINS (mU/L)[§](#jdi12172-note-0001){ref-type="fn"}   25.2 (14.8--42.8)    27.0 (15.8--45.8)                                      29.7 (17.2--50.7)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}    30.6 (18.0--53.7)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}
  HBCI[§](#jdi12172-note-0001){ref-type="fn"}            93.8 (63.8--142.1)   91.2 (61.9--140.2)                                     92.3 (61.8--144.5)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}   92.9 (60.8--140.5)
  HOMA‐IR[§](#jdi12172-note-0001){ref-type="fn"}         1.57 (1.11--2.21)    1.58 (1.12--2.27)                                      1.69 (1.18--2.48)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}    1.79 (1.24--2.63)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  BMI (kg/m^2^)                                          23.87 (0.03)         24.13 (0.04)[\*](#jdi12172-note-0001){ref-type="fn"}   24.39 (0.06)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}         24.87 (0.05)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  WC (cm)                                                81.61 (0.08)         82.17 (0.11)[\*](#jdi12172-note-0001){ref-type="fn"}   82.72 (0.17)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}         83.91 (0.12)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  TC (mmol/L)                                            4.68 (0.01)          4.71 (0.01)[\*](#jdi12172-note-0001){ref-type="fn"}    4.79 (0.02)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}          4.80 (0.12)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}
  TG (mmol/L)                                            1.50 (0.01)          1.54 (0.01)[\*](#jdi12172-note-0001){ref-type="fn"}    1.61 (0.02)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}          1.74 (0.01)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  HDL‐C (mmol/L)                                         1.33 (0.00)          1.34 (0.00)                                            1.34 (0.01)                                                                                         1.33 (0.00)
  LDL‐C (mmol/L)                                         2.76 (0.01)          2.75 (0.01)                                            2.77 (0.02)                                                                                         2.79 (0.01)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}
  SBP (mmHg)                                             119.9 (0.13)         122.5 (0.19)[\*](#jdi12172-note-0001){ref-type="fn"}   124.4 (0.30)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}         127.4 (0.21)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  DBP (mmHg)                                             77.2 (0.08)          78.8 (0.12)[\*](#jdi12172-note-0001){ref-type="fn"}    79.8 (0.19)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}          81.4 (0.13)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  UA (umol/L)                                            221.3 (1.53)         218.8 (2.28)                                           232.5 (3.75)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}         236.5 (2.75)[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}
  HOMA‐IR (%)                                                                                                                                                                                                                            
  \>1.79(75th percentile)                                39.26                40.16                                                  45.43[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                49.91[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  IGR (%)                                                13.80                15.74[\*](#jdi12172-note-0001){ref-type="fn"}          18.51[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                20.14[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  DM (%)                                                 4.60                 6.04\*                                                 8.84[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                 11.37[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  Dyslipidemia (%)                                       53.58                54.41                                                  57.21[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                61.11[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  Hypertension (%)                                       21.11                27.66[\*](#jdi12172-note-0001){ref-type="fn"}          34.1[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                 41.84[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  Overweight/obesity (%)                                                                                                                                                                                                                 
  CDS criteria                                           24.32                27.09[\*](#jdi12172-note-0001){ref-type="fn"}          31.14[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                35.56[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  IDF criteria                                           33.63                38.74[\*](#jdi12172-note-0001){ref-type="fn"}          42.36[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                48.24[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  MS (%)                                                                                                                                                                                                                                 
  CDS criteria                                           15.36                18.26[\*](#jdi12172-note-0001){ref-type="fn"}          23.37[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                30.27[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}
  IDF criteria                                           21.01                25.61[\*](#jdi12172-note-0001){ref-type="fn"}          30.15[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}                38.08[\*](#jdi12172-note-0001){ref-type="fn"}[†](#jdi12172-note-0001){ref-type="fn"}[‡](#jdi12172-note-0001){ref-type="fn"}

Data shown are mean (standard error) for normal distribution variables, interquartile notation for non‐normal distribution variables, and proportions for categorical variables. \*Versus albumin‐to‐creatinine ratio (ACR) 0--10 mg/g; †versus ACR 10--20 mg/g; ‡versus ACR 20--30 mg/g, *P* \< 0.05, adjusted for age and sex. 2hPG, 2‐h plasma glucose; 2hPINS, 2‐h plasma insulin; BMI, body mass index; CDS, Chinese Diabetes Society; DBP, diastolic blood pressure; DM, diabetes mellitus; FINS, fasting insulin; FPG, fasting plasma glucose; HBCI, homeostasis model assessment of β‐cell function index; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostasis model assessment of insulin resistance index; IDF, International Diabetes Federation; IGR, impaired glucose regulation; LDL‐C, low‐density lipoprotein cholesterol; MS, metabolic syndrome; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; UA, uric acid; WC, waist circumference. §Natural log transformation was applied before analyzing.

John Wiley & Sons, Ltd

In the NGT group, the median, fifth and 95th percentile values of ACR were 8.6 mg/g, 1.6 mg/g and 74.0 mg/g for men, and 11.7 mg/g, 2.0 mg/g and 87.8 mg/g for women. In the IGR group, those values of ACR were 11.0 mg/g, 1.9 mg/g and 103.7 mg/g for men, and 14.5 mg/g, 2.5 mg/g and 113.1 mg/g for women (participants with BMI values above the 99th percentile and below the 1st percentile in both groups were excluded from the analyses). In both groups, women had a higher age‐adjusted ACR than men (*P* \< 0.05). Figures [1](#jdi12172-fig-0001){ref-type="fig"} and [2](#jdi12172-fig-0002){ref-type="fig"} show the differences in the frequency of albuminuria by using a single ACR cut‐point, and by using sex‐specific ACR cut‐points in the NGT and IGR groups. The sex‐specific ACR cut‐points were lower for both men and women (14 mg/g for men and 20 mg/g for women). Thus, the use of sex‐specific ACR cut‐points increased the total prevalence of microalbuminuria. Results showed the prevalence of albuminuria was higher in men than in women.

![Distribution of albuminuria in non‐diabetes population. A single albumin‐to‐creatinine ratio cut‐point is defined as albumin‐to‐creatinine ratio ≥30 mg/g. IGR, impaired glucose regulation; NGT, normal glucose tolerance.](jdi-5-464-g1){#jdi12172-fig-0001}

![Distribution of albuminuria in non‐diabetes population. The sex‐specific albumin‐to‐creatinine ratio cut‐point is defined as albumin‐to‐creatinine ratio ≥14 mg/g for men and ≥20 mg/g for women. IGR, impaired glucose regulation; NGT, normal glucose tolerance.](jdi-5-464-g2){#jdi12172-fig-0002}

Factors associated with the presence of albuminuria were explored by multiple logistic regression analysis (Table [2](#jdi12172-tbl-0002){ref-type="table-wrap"}). Age, sex, glucose tolerance status, dyslipidemia, hypertension, BMI (or central obesity), IR, HOMA‐β cell function index (HBCI), uric acid, previous CVD and DMFH were entered as independent variables in the model. Results showed that older age (≥70 years, odds ratio \[OR\] 2.07, 95% confidence interval \[CI\] 1.65 --2.60; age 60 --70 years, OR 1.48, 95% CI 1.24 --1.77 vs age 20 --30 years), women (OR 1.7, 95% CI 1.55 --1.87 vs men), hypertension (OR 1.89, 95% CI 1.71 --2.10 vs no hypertension), hyperglycemia (IFG/IGT, OR 1.56, 95% CI 1.20 --2.04; newly diagnosed diabetes mellitus, OR 1.56, 95% CI 1.32 --1.84 vs NGT) and BMI (≥28 kg/m^2^, OR 1.43, 95% CI 1.26 --1.62 vs BMI \<24 kg/m^2^) were the greatest significant contributors to risk of albuminuria. Other factors (for example, IGT, dyslipidemia, insulin resistance, central obesity), although statistically significant, explained successively smaller proportions of the deviance and contributed little to the overall predicted risk. MS was also an independent risk factor for developing albuminuria, and the adjusted OR was 1.86 (95% CI 1.67 --2.07, *P* = 0.000) by CDS criteria and 1.59 (95% CI 1.45 --1.75, *P* = 0.000) by IDF criteria.

###### Risk factors associated with presence of albuminuria (albumin‐to‐creatinine ratio 30 --300 mg/g)

                                                     *n*      Albuminuria (%)   OR (95% CI)          *P*
  -------------------------------------------------- -------- ----------------- -------------------- -------
  Sex                                                                                                
  Men                                                15,003   16.4              1                    0.000
  Women                                              23,200   21.7              1.7 (1.55 --1.87)    
  Age (years)                                                                                        
  20 --30                                            6,041    15.3              1                    
  30 --40                                            8,762    16.9              0.96 (0.81 --1.13)   0.583
  40 --50                                            9,549    18.8              0.99 (0.84 --1.15)   0.928
  50 --60                                            8,104    20.7              1.14 (0.97 --1.34)   0.124
  60 --70                                            4,297    26.6              1.48 (1.24 --1.77)   0.000
  \>70                                               1,450    33.2              2.07 (1.65 --2.60)   0.000
  Glucose status                                                                                     
  NGT                                                29,543   17.3              1                    
  IFG                                                1,254    19.9              1.14 (0.86 --1.50)   0.363
  IGT                                                3,994    24.6              1.19 (1.03 --1.36)   0.016
  IFG/IGT                                            855      31.5              1.56 (1.20 --2.04)   0.001
  Newly diagnosed DM                                 2,557    33.1              1.56 (1.32 --1.84)   0.000
  Hypertension                                                                                       
  No                                                 27,489   15.8              1                    0.000
  Yes                                                10,714   29.1              1.89 (1.71 --2.10)   
  Dyslipidemia                                                                                       
  No                                                 16,958   17.1              1                    0.000
  Yes                                                21,245   21.4              1.18 (1.08 --1.30)   
  Insulin resistance                                                                                 
  No                                                 20,202   17.1              1                    0.015
  Yes                                                14,749   23.4              1.13 (1.02 --1.24)   
  BMI (kg/m^2^)                                                                                      
  \<24                                               19,999   16.3              1                    
  24 --28                                            12,502   21.0              1.17 (1.06 --1.30)   0.002
  ≥28                                                5,611    27.5              1.43 (1.26 --1.62)   0.000
  CVD                                                                                                
  No                                                 37,265   19.3              1                    0.107
  Yes                                                938      27.3              1.22 (0.96 --1.57)   
  Central obesity                                                                                    
  No                                                 27,494   17.4              1                    0.001
  Yes                                                10,622   24.9              1.19 (1.07 --1.31)   
  MS (CDS)[\*](#jdi12172-note-0002){ref-type="fn"}                                                   
  No                                                 30,650   17.0              1                    0.000
  Yes                                                7,553    29.9              1.86 (1.67 --2.07)   
  MS (IDF)[\*](#jdi12172-note-0002){ref-type="fn"}                                                   
  No                                                 28,128   16.4              1                    0.000
  Yes                                                10,075   28.2              1.59 (1.45 --1.75)   

Odds ratio and *P*‐value after mutually adjustment for multiple risk factors. \*Adjusted for age, sex, cardiovascular disease (CVD) and diabetes mellitus family history. BMI, body mass index; CDS, Chinese Diabetes Society; CI, confidence interval; DM, diabetes mellitus; IDF, International Diabetes Federation; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; OR, odds ratio.
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Table [3](#jdi12172-tbl-0003){ref-type="table-wrap"} shows the prevalence and odds ratio of CVD according to the ACR levels. There was a graded relationship between the ACR level and the CVD prevalence. Compared with the ACR level 0‐10 mg/g, the age and sex adjusted OR of CVD was 1.21 (95% CI 1.02 --1.43, *P* = 0.033) for the ACR level 10 --20 mg/g, 1.21 (95% CI 0.97 --1.52, *P* = 0.096) for the ACR level 20 --30 mg/g and 1.31 (95% CI 1.11 --1.56, *P* = 0.002) for the ACR level ≥30 mg/g. However, the further MS adjusted OR of CVD showed little statistical significance. After adjusting other CVD risk factors (2hPG, LDL‐C, DBP, HOMA‐IR, WC), the statistical significance did not exist.

###### Prevalence and odds ratio of cardiovascular disease in different albumin‐to‐creatinine ratio groups

  ACR (mg/g)   *n*      CVD (%)   OR (95%CI)[\*](#jdi12172-note-0003){ref-type="fn"}   *P*     OR (95% CI)[†](#jdi12172-note-0003){ref-type="fn"}   *P*     OR (95% CI)[‡](#jdi12172-note-0003){ref-type="fn"}   *P*
  ------------ -------- --------- ---------------------------------------------------- ------- ---------------------------------------------------- ------- ---------------------------------------------------- -------
  0 --10       17,564   1.89      1                                                    0.013   1                                                    0.134   1                                                    0.521
  10 --20      9,423    2.47      1.21 (1.02 --1.43)                                   0.033   1.19 (1.00 --1.41)                                   0.054   1.14 (0.94 --1.39)                                   0.195
  20 --30      3,765    2.79      1.21 (0.97 --1.52)                                   0.096   1.16 (0.92 --1.46)                                   0.204   1.12 (0.86 --1.45)                                   0.412
  30 --300     7,451    3.40      1.31 (1.11 --1.56)                                   0.002   1.19 (1.00 --1.42)                                   0.046   1.13 (0.92 --1.37)                                   0.244

\*Adjusted for age and sex. †Adjusted for age, gender and metabolic syndrome. ‡Mutually adjusted for multiple risk factors: age, sex, and other cardiovascular disease (CVD) risk factors (2‐h plasma glucose, low‐density lipoprotein cholesterol, diastolic blood pressure, homeostasis model assessment of insulin resistance, wait circumference). ACR, albumin‐to‐creatinine ratio; CI, confidence interval; OR, odds ratio.
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Discussion {#jdi12172-sec-0012}
==========

Microalbuminuria is an early sign of progressive cardiovascular and renal disease. Many epidemiological investigations for albuminuria have been carried out[8](#jdi12172-bib-0008 jdi12172-bib-0025){ref-type="ref"}. The National Health and Nutrition Examination Survey[25](#jdi12172-bib-0025){ref-type="ref"} showed age‐standardized prevalence of albuminuria of 11.0% and 14.3% for men and women in the USA, respectively. A recent national survey in China reported that albuminuria prevalence was 9.4% in the general population[8](#jdi12172-bib-0008){ref-type="ref"}. The overall prevalence of albuminuria (ACR ≥30 mg/g) in the present study was 19.5%, much higher than that in the previous study. Several factors could contribute to this inconsistency, such as different characteristics of participants, racial/ethnic difference[26](#jdi12172-bib-0026){ref-type="ref"}, diurnal fluctuation in albumin excretion[27](#jdi12172-bib-0027){ref-type="ref"}, and difference in collection, handling, storage and laboratory conditions[28](#jdi12172-bib-0028){ref-type="ref"}. A survey[29](#jdi12172-bib-0029){ref-type="ref"} carried out among general practitioners in nine European countries found that repeated tests were requested by 45% --77% of patients if the first test was positive, with considerable variations described in the type of samples tested and reported measurement units. Results from the National Health and Nutrition Examination Survey[25](#jdi12172-bib-0025){ref-type="ref"} also highlight differences in national prevalence estimates for albuminuria. In that survey, overall, just 43.5% of adults with increased ACR (\>30 mg/g) in a random urine sample also had increased ACR in a repeated morning urine test. The first and second screening results within 3 months of ACR had 69.2 --73.3% concordance according to studies[30](#jdi12172-bib-0030 jdi12172-bib-0031){ref-type="ref"} in Asia. These studies show that screening and diagnosis of albuminuria should be made more practicable, addressing issues such as type of samples, measurement units and repeat tests. As a single‐screening design tends to produce a higher prevalence estimate, it might be reasonable that at least two of the three urinary collections were carried out in a 3 --6 month period because of the variability in albumin excretion[31](#jdi12172-bib-0031){ref-type="ref"}.

Concerns have been expressed that the commonly cited 30 mg/g as "normal" might not be appropriate for patients of all ages, sexes and ethnicities[27](#jdi12172-bib-0027){ref-type="ref"}. Several studies have showed that the relationship between urinary excretion of albumin and CVD mortality is linear and not categorical, which is already apparent at levels of albuminuria currently considered to be normal[14](#jdi12172-bib-0014 jdi12172-bib-0015 jdi12172-bib-0016 jdi12172-bib-0017){ref-type="ref"}. An 8‐year follow‐up study[14](#jdi12172-bib-0014){ref-type="ref"} showed that compared with the albumin excretion rate (AER) ≤10 mg/24 h group, the ORs for any cardiovascular end‐point were 1.9 (95% CI 0.8 --2.5, *P* = 0.22) and 9.8 (95% CI 6.7 --12.3, *P* = 0.001) for the AER 10.1 --20 mg/24 h group and 20.1 --30 mg/24 h group, respectively. Urinary albumin concentration (UAC) increasing from 5 to 10 mg/L or 20 to 40 mg/L was associated with a 1.29‐fold higher risk for cardiovascular death, and the 2‐year cumulative incidence of cardiovascular death was 0.12% for UAC of 3.8 mg/L and 0.15% for UAC of 9.8 mg/L[16](#jdi12172-bib-0016){ref-type="ref"}. Another prospective study[17](#jdi12172-bib-0017){ref-type="ref"} also found that participants with urinary ACR (UACR) in the higher quartiles (UACR of 5.4 --10.2 mg/g for men and 7.6 --12.9 mg/g for women; UACR of 10.2 --30 mg/g for men and 12.9 --30 mg/g for women) had 41% and 72% greater risks of all CVD incidence, and 118% and 199% greater risks of death as a result of CVD than those in the lowest quartile (UACR of 0 --2.7 mg/g for men and 0 --4.3 mg/g for women). A high prevalence of CVD for urinary ACR within the normal range was also found in the present study, although the OR for CVD showed little or no statistical significance after adjusting for the conventional CVD risk factors. As the present study was a cross‐sectional survey, the causal relationship between albuminuria and CVD could not be made.

The current definition of microalbuminuria as an ACR level between 30 and 300 mg/g in both men and women in a random urine specimen does not take into account sex differences in creatinine excretion. Creatinine is a metabolic byproduct of skeletal muscle creatine and phosphocreatine metabolism, and is thus lower in subjects with lower muscle mass, such as women or the elderly[32](#jdi12172-bib-0032){ref-type="ref"}. In the present study, the higher frequency of microalbuminuria among women, defined by an ACR \>30 mg/g, is in part as a result of lower urine creatinine concentrations. The reported sex‐specific ACR reference value (the 95th percentile) in a healthy Beijing population was 14 mg/g (1.58 mg/mmol) for men and 20 mg/g (2.26 mg/mmol) for women[19](#jdi12172-bib-0019){ref-type="ref"}. This value is much lower than that of the 95th percentile in the present study, which was 74 mg/g for men and 87.8 mg/g for women in the NGT group. The discrepancy might be related to the different inclusion criteria for healthy participants. The present study analyzed the total NGT group (only excluding BMI above the 95th percentile and below the 1st percentile), which did not exclude subjects with hypertension, dyslipidemia, CVD, obesity or underweight condition, as well as those with an estimated glomerular filtration rate \>200 mL/min/1.73 m^2^ or \<60 mL/min/1.73 m^2^. As standardizing urinary ACR could underestimate microalbuminuria in subjects with higher muscle mass (men) or overestimate it in subjects with lower muscle mass (women), future research studies that use the ACR to define microalbuminuria should use sex‐specific ACR cut‐points to help avoid this potential problem. According to the present study, the sex‐specific prevalence of albuminuria increased obviously in both the NGT and the IGR groups. Studies have shown that lowering of albuminuria, started at an early phase, was associated with better renal and cardiovascular outcomes with and without diabetes[33](#jdi12172-bib-0033 jdi12172-bib-0034 jdi12172-bib-0035){ref-type="ref"}. The higher albuminuria prevalence no doubt would increase the burden of healthcare. Thus, results from prospective studies should be used to define the risk of abnormal urinary albumin excretion by sex, and by different levels of ACR. Besides, cut‐off levels should also be defined depending on the cost‐effectiveness of screening for albuminuria and treatment to lower albuminuria in an attempt to prevent CVD and CKD.

The present study re‐affirms previous observations[1](#jdi12172-bib-0001 jdi12172-bib-0003 jdi12172-bib-0004 jdi12172-bib-0008 jdi12172-bib-0036 jdi12172-bib-0037){ref-type="ref"} that aging, female sex, IGT, IR, hypertension, obesity, dyslipidemia, history of CVD and MS are independent risk factors for the presence of albuminuria. Therefore, although cost‐effectiveness studies of intervention for albuminuria in the general population are still required[38](#jdi12172-bib-0038){ref-type="ref"}, it seems sensible to implement early screening strategies for the prevention and treatment of albuminuria in subjects with high‐risk factors for albuminuria.

The present study had the strength of being a large, national cohort. However, it had several limitations. First, albuminuria was estimated based on a single urine specimen and, as we aforementioned, the variability in albumin excretion might lead to overestimation of the prevalence of albuminuria. We do not have the ability to confirm the increased ACR results because of financial and energy issues. Additionally, the cross‐sectional design of the present study makes it difficult to infer a causal relationship between albuminuria and associated factors or CVD. A follow‐up study is required to determine the factors and outcomes involved in the development of albuminuria. Furthermore, the lack of availability of serum creatinine to further indicate severity of renal dysfunction was also a limitation.

In summary, the prevalence of albuminuria is high in the general Chinese population. Aging, female sex, hypertension, hyperglycemia, dyslipidemia, IR, central obesity and MS are all independent risk factors. In light of the high rate of albuminuria, a screening strategy for the early recognition of CKD should be launched to prevent further progression, and education strategies for awareness of CKD among those high‐risk populations should be developed. Before this, efforts are required to standardize urine collection methods and the sex‐specific reference system. In addition, further follow‐up studies would assist our understanding of the natural history and outcomes of albuminuria in the general population, as well as the determinants for development of albuminuria.
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